Hemodialysis patients respond better to hepatitis B vaccination if they are receiving more efficient dialysis, as measured by Kt/V, Croatian researchers report.
Dr. Vedran Kovacic and colleagues from the Trogir Health Centre note in the journal Intervirology that patients on chronic haemodialysis generally have a weak response to vaccination with recombinant hepatitis B virus surface antigen (HbsAg).
To shed light on the association they conducted a study in 30 subjects. The clinicians administered HbsAg vaccine at 0, 1, 2, and 6 months to all participants. Those who had HbsAg antibody levels below 10 IU/L after vaccination were given a booster dose.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!